Quanterix Corp. (QTRX) PT Lowered to $15 at TD Cowen

TD Cowen analyst Dan Brennan lowered the price target on Quanterix Corp. (NASDAQ: QTRX) to $15.00 (from $17.00) while maintaining a Hold rating.

The analyst commented, "Q2 sales beat by 2% w/ GM also better but the guide was cut on weak instrument placements (cash burn also guided worse). Key 2Q positives were Accelerator strength (+17% Q/Q to record revenue levels) and strong multi-marker data. There are many moving pieces for the blood-based Alz testing oppty/ramp, & mgmt expects a material traction/ramp to occur in '25 w/ QTRX a key beneficiary."

You May Also Be Interested In

• York Space Systems (YSS) PT Lowered to $15 at Jefferies
• EyePoint Inc. (EYPT) PT Lowered to $8 at Jefferies
• BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy